vs
PTC THERAPEUTICS, INC.（PTCT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是PTC THERAPEUTICS, INC.的1.3倍（$207.3M vs $164.7M），Ultragenyx Pharmaceutical Inc.净利率更高（-62.0% vs -82.0%，领先19.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -22.7%），PTC THERAPEUTICS, INC.自由现金流更多（$-36.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -11.5%）
PTC Therapeutics是一家总部位于美国的制药企业，专注于开发口服小分子药物及基因疗法，通过靶向转录后调控机制调节基因表达，相关产品管线主要面向罕见病治疗领域，致力于满足相关疾病未被覆盖的临床治疗需求。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PTCT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $164.7M | $207.3M |
| 净利润 | $-135.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -43.3% | -54.7% |
| 净利率 | -82.0% | -62.0% |
| 营收同比 | -22.7% | 25.9% |
| 净利润同比 | -104.8% | 3.5% |
| 每股收益（稀释后） | $-1.63 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $164.7M | $207.3M | ||
| Q3 25 | $211.0M | $159.9M | ||
| Q2 25 | $178.9M | $166.5M | ||
| Q1 25 | $1.2B | $139.3M | ||
| Q4 24 | $213.2M | $164.6M | ||
| Q3 24 | $196.8M | $139.5M | ||
| Q2 24 | $186.7M | $147.0M | ||
| Q1 24 | $210.1M | $108.8M |
| Q4 25 | $-135.0M | $-128.6M | ||
| Q3 25 | $15.9M | $-180.4M | ||
| Q2 25 | $-64.8M | $-115.0M | ||
| Q1 25 | $866.6M | $-151.1M | ||
| Q4 24 | $-65.9M | $-133.2M | ||
| Q3 24 | $-106.7M | $-133.5M | ||
| Q2 24 | $-99.2M | $-131.6M | ||
| Q1 24 | $-91.6M | $-170.7M |
| Q4 25 | -43.3% | -54.7% | ||
| Q3 25 | 1.4% | -106.9% | ||
| Q2 25 | -19.5% | -64.8% | ||
| Q1 25 | 82.5% | -102.6% | ||
| Q4 24 | -76.2% | -74.3% | ||
| Q3 24 | -27.7% | -94.6% | ||
| Q2 24 | -21.5% | -79.1% | ||
| Q1 24 | -21.6% | -151.9% |
| Q4 25 | -82.0% | -62.0% | ||
| Q3 25 | 7.5% | -112.8% | ||
| Q2 25 | -36.3% | -69.0% | ||
| Q1 25 | 73.7% | -108.5% | ||
| Q4 24 | -30.9% | -80.9% | ||
| Q3 24 | -54.2% | -95.7% | ||
| Q2 24 | -53.1% | -89.5% | ||
| Q1 24 | -43.6% | -156.8% |
| Q4 25 | $-1.63 | $-1.28 | ||
| Q3 25 | $0.20 | $-1.81 | ||
| Q2 25 | $-0.83 | $-1.17 | ||
| Q1 25 | $10.04 | $-1.57 | ||
| Q4 24 | $-0.85 | $-1.34 | ||
| Q3 24 | $-1.39 | $-1.40 | ||
| Q2 24 | $-1.29 | $-1.52 | ||
| Q1 24 | $-1.20 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9B | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-205.3M | $-80.0M |
| 总资产 | $2.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $1.9B | $421.0M | ||
| Q3 25 | $1.7B | $202.5M | ||
| Q2 25 | $2.0B | $176.3M | ||
| Q1 25 | $2.0B | $127.1M | ||
| Q4 24 | $1.1B | $174.0M | ||
| Q3 24 | $1.0B | $150.6M | ||
| Q2 24 | $1.1B | $480.7M | ||
| Q1 24 | $884.8M | $112.3M |
| Q4 25 | $-205.3M | $-80.0M | ||
| Q3 25 | $-155.8M | $9.2M | ||
| Q2 25 | $-206.5M | $151.3M | ||
| Q1 25 | $-185.8M | $144.2M | ||
| Q4 24 | $-1.1B | $255.0M | ||
| Q3 24 | $-1.1B | $346.8M | ||
| Q2 24 | $-980.2M | $432.4M | ||
| Q1 24 | $-893.9M | $140.3M |
| Q4 25 | $2.9B | $1.5B | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.7B | $1.3B | ||
| Q4 24 | $1.7B | $1.5B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.9B | $1.6B | ||
| Q1 24 | $1.8B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-34.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-36.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | -22.3% | -48.6% |
| 资本支出强度资本支出/营收 | 1.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $702.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-34.3M | $-99.8M | ||
| Q3 25 | $-66.3M | $-91.4M | ||
| Q2 25 | $-58.3M | $-108.3M | ||
| Q1 25 | $870.1M | $-166.5M | ||
| Q4 24 | $-30.0M | $-79.3M | ||
| Q3 24 | $-77.0M | $-67.0M | ||
| Q2 24 | $-71.5M | $-77.0M | ||
| Q1 24 | $70.8M | $-190.7M |
| Q4 25 | $-36.6M | $-100.8M | ||
| Q3 25 | $-69.7M | $-92.7M | ||
| Q2 25 | $-59.6M | $-110.7M | ||
| Q1 25 | $868.4M | $-167.8M | ||
| Q4 24 | $-33.8M | $-79.5M | ||
| Q3 24 | $-77.5M | $-68.6M | ||
| Q2 24 | $-78.8M | $-79.0M | ||
| Q1 24 | $61.2M | $-193.9M |
| Q4 25 | -22.3% | -48.6% | ||
| Q3 25 | -33.1% | -58.0% | ||
| Q2 25 | -33.3% | -66.5% | ||
| Q1 25 | 73.8% | -120.5% | ||
| Q4 24 | -15.8% | -48.3% | ||
| Q3 24 | -39.4% | -49.2% | ||
| Q2 24 | -42.2% | -53.7% | ||
| Q1 24 | 29.1% | -178.2% |
| Q4 25 | 1.4% | 0.5% | ||
| Q3 25 | 1.6% | 0.8% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.1% | 1.0% | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 0.3% | 1.2% | ||
| Q2 24 | 4.0% | 1.4% | ||
| Q1 24 | 4.6% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | -4.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PTCT
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
